Elsevier

Leukemia Research

Volume 37, Issue 11, November 2013, Pages 1404-1411
Leukemia Research

Invited review
Hematogones: An overview

https://doi.org/10.1016/j.leukres.2013.07.024Get rights and content

Abstract

Hematogones were initially described as mysterious cells in bone marrow smears more than 70 years ago. These cells are normal bone marrow B-lymphocyte precursors with properties that overlap those of lymphoblasts. Their morphological and immunological features are described here with an update on the knowledge of hematogones in hematological and non-hematological disorders.

Section snippets

History of hematogones

Hematogones (B-lymphocyte precursors) were first described in 1937 by Peter Vogel as “lymphoid-appearing cells” in bone marrow aspirates from children [1]. The term hematogones comes from the Latin term “hematogonia” meaning “blood-maker” and describes cells of uncertain significance.

For several decades their origin and function were unknown. Several terms have been used to describe these immature, lymphoid-appearing bone marrow cells, including marrow precursor cells [2], post-therapeutic stem

Morphologic features

Hematogones (HGs) are lymphoid-appearing cells. A bone marrow trephine biopsy study of HGs-rich specimens showed that the most immature cells were diffusely dispersed within the bone marrow without significant clustering [31].

Examination of bone marrow smears allowed a better appreciation of their cytological characteristics [32]. Although the diameter varied from 10 to 20 μ, these morphologically distinct cells characteristically exhibit highly condensed, uniform nuclear chromatin and scant

Immunophenotypic features

With the arrival of multi-parametric FC and peroxidase staining, HGs were identified as bone marrow B-cells precursors. HGs are non reactive with Sudan black B, myeloperoxidase and non-specific esterase stains [6], [8]. Flow cytometry has become the most useful tools for characterizing HGs [7], [17], [29]. Several studies have described the different stage of HG development [8], [9], [42]. Fig. 2 depicts the phenotypic characteristics of the three stages of HGs.

The most immature recognizable

HG localization

HG detection by morphologic examination in peripheral blood has been performed in neonates [5], [19], [28] and blood from umbilical cord blood [3], [8], [34]. They are usually identified in the majority of bone marrow samples using a 4-color flow cytometry assay [31], [43]. They can also be identified using sensitive flow cytometry in the peripheral blood in 65% of adults with various clinical conditions. Only mature HGs (stage 3) were found, comprising 0.01–1.3% of WBCs (median 0.06%, mean

Minimal residual disease detection in ALL

The most important application of HG's phenotype knowledge is to distinguish HGs from minimal residual disease in patients treated for B-ALL. Currently, the most reliable method to study MRD in ALL is flow cytometric analysis of leukemia-associated immunophenotypes (LAiP) (aberrant phenotypes expressed in leukemic cells but not in normal bone marrow cells). Aberrant immunophenotypes are found in more than 90% of patients with newly diagnosed ALL and that would allow the detection of MRD at the

Conclusion

HGs are normal B-cell precursors first described more than 70 years ago. Their recognition by flow cytometry has led to the study of HGs in several pathological conditions. However in healthy individuals, the normal number of HGs in the bone marrow remains unknown. The main characteristic of the HG phenotype is continuous and discrete antigen maturation patterns. There is not a unique phenotype but rather a dynamic evolution of antigens that distinguishes HGs. The identification of HGs is

Acknowledgments

Contributors: S.P.C and O.R designed the study. S.P.C, E.C, V.S, A.C.G, O.R wrote the paper. E.C and V.S provided pictures and flow cytometry graphs. All authors critically revised the manuscript and approved the final version of the manuscript.

The authors declare no competing financial interests.

References (104)

  • N. Breslow et al.

    A note on the relationship between bone marrow lymphocytosis and remission duration in acute leukemia

    Blood

    (1970)
  • E.R. Pearl

    Pre-B-cells in normal human bone marrow and in bone marrow from patients with leukemia in remission: persistent quantitative differences and possible expression of cell surface IgM in vitro

    Blood

    (1983)
  • G. Janossy et al.

    Cellular phenotypes of normal and leukemic hemopoietic cells determined by analysis with selected antibody combinations

    Blood

    (1980)
  • M.F. Greaves et al.

    Selective expression of the common acute lymphoblastic leukemia (gp 100) antigen on immature lymphoid cells and their malignant counterparts

    Blood

    (1983)
  • T.W. Froehlich et al.

    Terminal deoxynucleotidyl transferase-containing cells in peripheral blood: implications for the surveillance of patients with lymphoblastic leukemia or lymphoma in remission

    Blood

    (1981)
  • R.W. McKenna et al.

    Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry

    Blood

    (2001)
  • E. Coustan-Smith et al.

    Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia

    Blood

    (1996)
  • D. Campana et al.

    Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein

    Blood

    (1993)
  • M. Hudecek et al.

    The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor

    Blood

    (2010)
  • H.E. Broome et al.

    ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia

    Leuk Res

    (2011)
  • T.A. Longacre et al.

    Hematogones: a multiparameter analysis of bone marrow precursor cells

    Blood

    (1989)
  • E. Koca et al.

    Copper deficiency with increased hematogones mimicking refractory anemia with excess blasts

    Leuk Res

    (2008)
  • A. Nogai et al.

    Frequency and relevance of CD10+ CD19+ hematogones after allogeneic stem cell transplantation

    ASH Annu Meeting Abstr

    (2008)
  • G. Tang et al.

    Multi-color CD34+ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia

    Leuk Res

    (2012)
  • A. Sternberg et al.

    Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome

    Blood

    (2005)
  • E. Ribeiro et al.

    Maturation-associated immunophenotypic abnormalities in bone marrow B-lymphocytes in myelodysplastic syndromes

    Leuk Res

    (2006)
  • K. Ogata et al.

    Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes

    Blood

    (2006)
  • S.P. Chantepie et al.

    Hematogones: a new prognostic factor for acute myeloblastic leukemia

    Blood

    (2011)
  • D. Pereira et al.

    Prognostic impact of high hematogones in acute myeloid leukemia

    ASH Annu Meeting Abstr

    (2012)
  • S.P. Chantepie et al.

    Prognostic impact of bone marrow B lymphocyte precursors (hematogones) detection in 95 acute lymphoblastic leukemia cases

    ASH Annu Meeting Abstr

    (2012)
  • U. Bacher et al.

    Prognostic impact of physiological B-cell precursors (hematogones) in the bone marrow as determined by immunophenotyping in the post-transplant period in patients with AML

    ASH Annu Meeting Abstr

    (2012)
  • T. Honebrink et al.

    Impact of bone marrow hematogones on umbilical cord blood transplantation outcomes in patients with acute myeloid leukemia

    Biol Blood Marrow Transplant

    (2012)
  • P.P. Montesinos et al.

    Significance of increased blastic-appearing cells in bone marrow following myeloablative unrelated cord blood transplantation in adult patients

    Biol Blood Marrow Transplant

    (2012)
  • P. Vogel et al.

    Hematological observations on bone marrow obtained by sternal puncture

    Am J Clin Pathol

    (1937)
  • J.H. Schuurmans Stekhoven et al.

    Morphology and incidence of the “posttherapeutic lymphoid cell” in the bone marrow of children with acute lymphoblastic leukemia

    Am J Pathol

    (1986)
  • J.W. Ibbott et al.

    The significant percentage of blast cells in the bone marrow in the diagnosis of acute leukaemia

    Can Med Assoc J

    (1960)
  • S. Woessner et al.

    Asymptomatic bone marrow infiltration by blast cells

    N Engl J Med

    (1985)
  • S.D. Muehleck et al.

    Terminal deoxynucleotidyl transferase (TdT)-positive cells in bone marrow in the absence of hematologic malignancy

    Am J Clin Pathol

    (1983)
  • G. Janossy et al.

    Terminal transferase-positive human bone marrow cells exhibit the antigenic phenotype of common acute lymphoblastic leukemia

    J Immunol

    (1979)
  • P.H. Hogeman et al.

    Common acute lymphoblastic leukemia antigen-positive cells in normal bone marrow

    Blood

    (1985)
  • P.H. Hogeman et al.

    Peanut agglutinin distinguishes CALLA positive reactive bone marrow cells from leukaemic blasts

    Br J Haematol

    (1985)
  • N. Ifrah et al.

    Persistence of bone marrow lymphocytosis after induction treatment in common acute lymphoblastic leukemia. Marker analysis and significance

    Cancer

    (1986)
  • P. Paolucci et al.

    Pre-B and B cells in children on leukaemia remission maintenance treatment

    Clin Exp Immunol

    (1979)
  • D. Fradelizi et al.

    Human Ia-like DRw lymphocyte antigens stimulating activity in primary mixed lymphocyte reaction

    Eur J Immunol

    (1978)
  • T.W. LeBien et al.

    Multiparameter flow cytometric analysis of human fetal bone marrow B cells

    Leukemia

    (1990)
  • C. Schmitt et al.

    Expression of CD34 on human B cell precursors

    Clin Exp Immunol

    (1991)
  • P. Hokland et al.

    Purification and characterization of fetal hematopoietic cells that express the common acute lymphoblastic leukemia antigen (CALLA)

    J Exp Med

    (1983)
  • K.A. Brady et al.

    Flow cytometric detection of CD10 (cALLA) on peripheral blood B lymphocytes of neonates

    Br J Haematol

    (1999)
  • M.R. Loken et al.

    Flow cytometric analysis of normal B lymphoid development

    Pathol Immunopathol Res

    (1988)
  • L.M. Rimsza et al.

    Benign hematogone-rich lymphoid proliferations can be distinguished from B-lineage acute lymphoblastic leukemia by integration of morphology, immunophenotype, adhesion molecule expression, and architectural features

    Am J Clin Pathol

    (2000)
  • Cited by (0)

    View full text